Ibrutinib for treatment of chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Ibrutinib for treatment of chronic lymphocytic leukemia

Published:2016-03-15 Issue:6 Volume:73 Page:367-375
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Vela Cory M.¹,McBride Ali²,Jaglowski Samantha M.³,Andritsos Leslie A.³

Affiliation:

1. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

2. University of Arizona Cancer Center, Tuscon, AZ

3. Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, OH

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/73/6/367/28334945/ajhp0367.pdf

Reference39 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. National Comprehensive Cancer Network. Non-Hodgkin’s lymphomas (version 2. 2015). www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (accessed 2015 Apr 27).

3. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute–Working Group 1996 guidelines;Hallek;Blood,2008

4. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group;Stilgenbauer;J Clin Oncol,2009

5. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia;Wierda;J Clin Oncol,2010

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models;CPT: Pharmacometrics & Systems Pharmacology;2023-07-26

2. High throughput LC/ESI-MS/MS method for simultaneous analysis of 20 oral molecular-targeted anticancer drugs and the active metabolite of sunitinib in human plasma;Heliyon;2023-06

3. Diagnostic Applications of Nuclear Medicine: Leukemias;Nuclear Oncology;2022

4. Diagnostic Applications of Nuclear Medicine: Leukemias;Nuclear Oncology;2022

5. Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study;The Korean Journal of Internal Medicine;2021-01-01